Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

CLASS ACTION UPDATE for NNOX, INNV and AMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

NNOX Shareholders Click Here: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-loss-submission-form?prid=20876&wire=1
INNV Shareholders Click Here: https://www.zlk.com/pslra-1/innovage-holding-inc-loss-submission-form-2?prid=20876&wire=1
AMRN Shareholders Click Here: https://www.zlk.com/pslra-1/amarin-corporation-plc-loss-submission-form?prid=20876&wire=1

* ADDITIONAL INFORMATION BELOW *

Nano-X Imaging Ltd. (NASDAQ:NNOX)

NNOX Lawsuit on behalf of: investors who purchased June 17, 2021 - August 18, 2021
Lead Plaintiff Deadline: December 6, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-loss-submission-form?prid=20876&wire=1

According to the filed complaint, during the class period, Nano-X Imaging Ltd. made materially false and/or misleading statements and/or failed to disclose that: (i) Nano-X's 510(k) application for the Nanox.ARC was deficient; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the 510(k) application for the Nanox.ARC in its current form; (iii) as a result, NanoX had overstated the Nanox.ARC's regulatory and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

InnovAge Holding Inc. (NASDAQ:INNV)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired InnovAge common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's March 2021 initial public offering.
Lead Plaintiff Deadline: December 13, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/innovage-holding-inc-loss-submission-form-2?prid=20876&wire=1

According to the filed complaint, (1) certain of InnovAge's facilities failed to provide covered services, provide accessible and adequate services, manage participants' medical situations, and oversee use of specialists; (2) as a result, the Company was reasonably likely to be subject to regulatory scrutiny, including by the Centers for Medicare and Medicaid Services; (3) as a result, there as a significant risk that CMS would suspend new enrollments pending an audit of the Company's services; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Amarin Corporation Plc (NASDAQ:AMRN)

AMRN Lawsuit on behalf of: investors who purchased December 5, 2018 - June 21, 2021
Lead Plaintiff Deadline: December 23, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/amarin-corporation-plc-loss-submission-form?prid=20876&wire=1

According to the filed complaint, during the class period, Amarin Corporation Plc made materially false and/or misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (ii) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (iii) the Company's litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company's business and future prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/671198/CLASS-ACTION-UPDATE-for-NNOX-INNV-and-AMRN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.